|--|

C**←**N T R U M

Refractories

HOLD

IFGL Refractories

12 December 2017

Strong domestic show saves the day, retain Hold

Result Update

We maintain our Hold rating on IFGL Refractories as we see limited scope for further re-rating after stock's large outperformance to MNC peers in line with our view in last one year. Q2 performance was a mixed bag with domestic operations delivering strong results largely negated by weak results across all overseas subs. We continue to like IFGL's operationally sound high-quality global assets and expect strong earnings growth driven by i) increased share of higher-margin subs and ii) recovery in steel production in key markets of US/Europe/India (aided by regulatory support & demand revival). Strong free cash flow visibility and a solid balance sheet are added positives but believe that valuations fully discount these.

- India operations deliver excellent show but overseas disappoint: Domestic operations delivered strong performance with revenue growth of ~23% YoY and EBITDA growth of 90% YoY to Rs219mn. EIC (US) delivered weak performance due to loss of a key customer and EBITDA dropped ~47% YoY to US\$0.43mn. European operations at both Monocon and Hoffmann had weak performance on both YoY and QoQ basis due to lower offtake and higher raw material costs.
- O Consolidated EBITDA marginally below estimates, higher tax provisioning supresses PAT: Consolidated EBITDA was down 9% YoY to Rs268mn and stood 3.6% below our estimates. Gross margins were under pressure due to higher RM costs and declined 380bps YoY to 50.2% and EBITDA margins stood at 13.4%. EBITDA margins were supported by strong margin performance at India operations. PAT remained supressed by goodwill write-off and higher deferred tax provisioning.
- Earnings revised marginally downwards: We lower our EBITDA estimates to account for headwinds at overseas operations and revise our PAT estimates downwards to account for higher deferred tax provisioning; however we note that cash flow impact remains positive from goodwill write-off and tax benefits on the same. Our FY18E/19E EBITDA/PAT estimates are revised downwards by 1.6%/0.9% and 7.7%/6.3% respectively.
- Valuation and risks: We expect EBITDA/PAT CAGR of 13.0%/14.2% during FY17-19E, led by volume growth and increased contributions from higher-margin operations of Kandla/US. The stock has seen significant re-rating in the last 12 months in line with our view and its large discount to the MNCs has narrowed significantly. At CMP of Rs323, trades at FY19E valuations of 20.2x P/E, 8.7x EV/EBITDA and 5 year FCF yield of 6.6% and further re-rating scope is limited in our view. We retain Hold with a revised TP of Rs310 based on 14x FY19E P/E applied to EPS adjusted for goodwill write-off. We have ascribed 30% discount to IFGL compared to its MNC peer and industry leader Vesuvius. Key upside risk is higher volumes while downside risk is higher raw material costs.

Y/E Mar-Cons (Rs mn)	Q2FY18	Q2FY17	YoY (%)	Q1FY18	QoQ (%)	Q2FY18E	Var. (%)
Net sales	1,992	1,929	3.3	1,978	0.7	1,994	(0.1)
Raw materials	992	888	11.7	1,008	(1.6)	997	(0.5)
Employee costs	310	309	0.4	326	(4.9)	319	(2.9)
EBITDA	268	294	(9.0)	246	8.6	277	(3.6)
EBITDA margin (%)	13.4	15.2		12.5		13.9	
Depreciation	107	105	1.7	107	0.2	110	(2.6)
Interest	9	10	(6.1)	11	(14.0)	11	(16.4)
PBT	158	195	(18.7)	136	16.7	166	(4.8)
Tax	64	18	262.1	23	173.9	33	92.6
PAT	94	177	(46.8)	112	(16.0)	133	(29.1)

Source: Company, Centrum Research Estimates

Target Pri	ce		Rs310	Key Data					
CMP*			Rs323	Bloomberg Code	IFGLRF IN				
Downside	Downside 4.1%		Curr Shares O/S (mn)	34.6					
Previous Target Rs320		Diluted Shares O/S(mn)							
Previous Rating Buy		Mkt Cap (Rsbn/USDmn)	11.8/183.8						
Price Perf	orman	ce (%)	*	52 Wk H / L (Rs)	354/154.5				
	1M	6M	1Yr	5 Year H / L (Rs)	354/23.5				
IFGLRF IN	0.0 32.0 8		83.4	Daily Vol. (20d NSE Avg.)	23334				
NIFTY	(0.8)	6.5	25.3						

*as on 12 December 2017; Source: Bloomberg, Centrum Research

Shareholding pattern (%)*

	Jun-17	Mar-17	Dec-16	Sept-16						
Promoter	71.3	71.3	71.3	71.3						
FIIs	0.1	0.1	0.0	0.0						
Dom. Inst.	5.0	4.3	3.1	2.1						
Public & Others	23.6	24.3	25.6	26.6						
Source: BSE, *as on 12 December 2017										

Subsidiary-wise quarterly key financials

(Rs mn)	Q2FY18	Q2FY17	YoY (%)	Q1FY18	QoQ (%)
Standalone merged					
Revenue	1,094	887	23.3	1,060	3.2
EBITDA	219	115	90.9	169	29.5
Margin %	20.0	12.9		16.0	
El Ceramics (\$ mn)					
Revenue	3.63	4.40	(17.5)	4.53	(19.9)
EBITDA	0.43	0.81	(47.2)	0.70	(38.6)
Margin %	11.8	18.5		15.5	
Monocon (GBP mn)					
Revenue	6.20	6.41	(3.2)	6.14	1.0
EBITDA	0.37	1.00	(62.9)	0.43	(14.0)
Margin %	6.0	15.6		7.0	
Hoffmann (Euro mn)					
Revenue	2.15	2.47	(13.0)	2.68	(19.8)
EBITDA	(0.01)	0.22	NA	0.01	NA
Margin %	(0.5)	9.0		0.4	

Earnings Revision (Cons)

Particulars*		FY18E		FY19E								
(Rs mn)	New	Old	Chg (%)	New	Old	Chg (%)						
Sales	7,981	8,077	(1.2)	8,887	9,111	(2.5)						
EBITDA	1,024	1,040	(1.6)	1,210	1,220	(0.9)						
EBITDA Margin (%)	12.8	12.9		13.6	13.4							
PAT	436	472	(7.7)	576	615	(6.3)						

Source: Centrum Research Estimates, *Merger factored in estimates

Abhisar Jain, CFA, abhisar.jain@centrum.co.in, 91 22 4215 9928

Y/E Mar(Rs mn)*	Rev	YoY (%)	EBITDA	EBITDA (%)	PAT	YoY (%)	EPS (Rs)	RoE (%)	RoCE (%)	P/E (x)	EV/EBITDA (x)
FY15	7,868	1.2	922	11.7	531	6.7	15.3	15.8	11.9	9.5	6.2
FY16	7,170	(8.9)	760	10.6	418	5.8	12.1	11.4	9.8	9.1	5.2
FY17	7,656	6.8	948	12.4	442	5.8	12.3	8.3	6.3	11.5	5.5
FY18E	7,981	4.2	1,024	12.8	436	5.5	12.1	6.2	6.0	26.7	10.8
FY19E	8,887	11.4	1,210	13.6	576	6.5	16.0	7.8	7.4	20.2	8.7

Source: Company, Centrum Research Estimates, *Financials from FY17 includes impact of Ind-As and Merger

In the interest of timeliness, this document is not edited

Centrum Equity Research is available on Bloomberg, Thomson Reuters and FactSet

C{NTRUM


Exhibit 1: Sensitivity Analysis (FY18E)

1% change	% Chg in EBITDA	% Chg in PAT
Realizations	1.7	1.6
Volumes	1.3	1.1

Exhibit 3: 1 year forward P/E chart

Source: Company, Centrum Research Estimates

Exhibit 2: 1 year EV/EBITDA chart



Source: Bloomberg, Company, Centrum Research Estimates

Source: Bloomberg, Company, Centrum Research Estimates

Exhibit 4: Valuation – Peer comparison

Company	Mkt. Cap CAGR CY16-CY18E		8E (%)	EBITDA Margin (%)		P/E (x)		EV/EBITDA (x)		RoE (%)		Div Yield (%)		(%)					
Company	(US\$ mn)	Rev.	EBITDA	PAT	CY16	CY17E	CY18E	CY16	CY17E	CY18E	CY16	CY17E	CY18E	CY16	CY17E	CY18E	CY16	CY17E	CY18E
IFGL Refractories*#	184	7.7	13.0	14.2	12.4	12.8	13.6	11.5	26.7	20.2	5.5	10.8	8.7	8.3	6.2	7.8	1.4	0.7	1.0
Vesuvius India	386	12.6	11.0	15.2	19.0	18.1	18.5	23.4	24.4	20.2	12.9	14.8	11.5	16.8	16.8	17.7	0.8	0.7	0.9
Orient Refractories#	298	13.4	14.1	15.7	19.5	19.5	19.7	18.6	25.0	21.1	12.5	16.9	13.8	28.8	25.3	24.8	1.7	1.4	1.6
Global Peers																			
Rhi Magnesita NV	2,530	(0.5)	3.9	(7.5)	14.0	14.7	15.2		16.0	14.0		5.6	5.3	17.8	17.1	16.3		1.6	1.8
Vesuvius PLC	2,026	9.2	19.2	23.2	11.8	13.0	14.0	14.3	15.0	13.1	8.3	8.7	8.2	8.4	9.1	10.1	4.3	3.2	3.3
Cie de St-Gobain	30,570	3.7	7.7	17.5	10.2	10.5	11.0	16.8	16.1	13.8	6.9	7.4	7.1	6.8	8.2	9.2	3.1	2.7	2.9

Source: Bloomberg consensus estimates, * Centrum Research Estimates, #CY16=FY17 for Orient, IFGL

C**√**N T R U M

Exhibit 5: Quarterly Financials (cons)

Y/E Mar (Rs mn)	Q3FY16	Q4FY16	Q1FY17*	Q2FY17*	Q3FY17	Q4FY17	Q1FY18*	Q2FY18*
Net sales	1,709	1,765	1,806	1,929	1,830	2,084	1,978	1,992
Accretion to Stocks in trade & work in progress	83	28	(42)	(60)	(49)	1	11	15
Cost of Raw Materials consumed	615	662	735	880	713	767	962	937
Purchase of traded goods	168	184	199	68	205	200	34	40
Staff Cost	286	323	310	309	309	323	326	310
Other Operational expenses	365	387	397	438	441	510	398	423
Operating Profit (Core EBITDA)	191	181	208	294	211	283	246	268
Depreciation	40	36	106	105	41	55	107	107
EBIT	151	145	101	189	171	228	139	160
Interest	11	11	11	10	10	14	11	9
Other Revenue/Income	9	14	16	16	3	7	7	7
Profit Before Tax	149	148	107	195	163	221	136	158
Tax	42	32	17	18	36	60	23	64
Profit After Tax	107	116	90	177	127	162	112	94
Minority Interest	5	10	0	0	20	25	0	0
Profit after minority interest	102	106	90	177	106	137	112	94
Growth (YoY %)								
Revenue	(10.9)	(8.4)	(2.2)	4.3	7.1	18.1	9.5	3.3
EBITDA	(15.0)	11.1	(17.1)	111.7	10.7	56.2	18.6	(9.0)
PAT	(17.7)	26.8	(40.8)	199.8	4.3	28.9	24.6	(46.8)
Margin (%)								
EBITDA	11.2	10.3	11.5	15.2	11.6	13.6	12.5	13.4
EBIT	8.8	8.2	5.6	9.8	9.3	11.0	7.0	8.1
PAT	6.0	6.0	5.0	9.2	5.8	6.6	5.7	4.7
Segment Revenue (Net Sales/ Income from ops)								
India	824	731	823	937	930	1,038	1,036	1,070
Asia (excl. India)	124	26	25	19	19	24	22	34
Europe	615	607	550	574	484	560	542	521
Americas	334	402	455	448	397	461	418	368
Segment EBIT								
India	76	67	52	35	102	162	78	126
Asia (excl. India)	13	14	15	13	21	23	11	0
Europe	70	52	12	70	21	-9	17	13
Americas	14	35	39	86	30	60	41	20

Source: Company, Centrum Research, * as per merged financials and accounting for Ind-AS

Financials (Cons)*

Exhibit 6: Income Statement

Y/E Mar(Rs mn)	FY15	FY16	FY17	FY18E	FY19E
Revenues	7,868	7,170	7,656	7,981	8,887
Materials cost	4,061	3,652	3,620	3,988	4,416
% of revenues	51.6	50.9	47.3	50.0	49.7
Employee cost	1,179	1,196	1,254	1,304	1,408
% of revenues	15.0	16.7	16.4	16.3	15.8
Others	1,706	1,562	1,834	1,665	1,853
% of revenues	21.7	21.8	24.0	20.9	20.9
EBITDA	922	760	948	1,024	1,210
EBITDA margin (%)	11.7	10.6	12.4	12.8	13.6
Depreciation & Amortisation	143	156	442	450	465
EBIT	779	604	507	573	745
Interest expenses	59	48	45	21	9
PBT from operations	720	557	461	552	735
Other income	67	51	27	30	33
Exceptional items	-	-	-	-	-
РВТ	787	608	488	582	768
Taxes	254	157	46	145	192
Effective tax rate (%)	32	26	10	25	25
РАТ	533	451	442	436	576
Minority/Associates	2	32	-0	-	-
Adjusted PAT	531	418	442	436	576

Source: Company data, Centrum Research Estimates

Exhibit 7: Key Ratios

Y/E Mar	FY15	FY16	FY17	FY18E	FY19E
Growth Ratio (%)					
Revenue	1.2	(8.9)	6.8	4.2	11.4
EBITDA	(15.9)	(17.5)	24.7	8.0	18.2
Adjusted PAT	(17.0)	(21.2)	5.6	(1.3)	32.1
Margin Ratios (%)					
EBITDA	11.7	10.6	12.4	12.8	13.6
PBT from operations	9.2	7.8	6.0	6.9	8.3
Adjusted PAT	6.7	5.8	5.8	5.5	6.5
Return Ratios (%)					
ROE	15.8	11.4	8.3	6.2	7.8
ROCE	11.9	9.8	6.3	6.0	7.4
ROIC	12.2	10.4	6.5	6.5	8.5
Turnover Ratios (days)					
Gross block turnover ratio (x)	1.9	1.7	1.3	1.1	1.2
Debtors	84	92	109	95	95
Inventory	46	39	45	42	42
Creditors	46	50	57	50	50
Cash conversion cycle	84	81	97	87	87
Solvency Ratio (x)					
Net debt-equity	0.2	0.0	0.0	(0.1)	(0.1)
Debt-equity	0.3	0.2	0.1	0.0	0.0
Interest coverage ratio	0.1	0.1	0.1	0.0	0.0
Gross debt/EBITDA	1.3	1.1	0.9	0.3	0.1
Current Ratio	3.0	3.2	3.2	3.4	3.5
Per share Ratios (Rs)					
Adjusted EPS	15.3	12.1	12.3	12.1	16.0
BVPS	99.6	111.7	189.9	199.2	211.4
CEPS	19.5	16.6	24.5	24.6	28.9
DPS	2.0	2.0	2.0	2.4	3.2
Dividend payout %	13.0	16.5	16.3	20.0	20.0
Valuation (x)*					
P/E (adjusted)	9.5	9.1	11.5	26.7	20.2
P/BV	1.5	1.0	0.7	1.6	1.5
EV/EBITDA	6.2	5.2	5.5	10.8	8.7
Dividend yield %	1.4	1.8	1.4	0.7	1.0
5 Yr Avg AOCF/EV yield %	6.2	11.9	8.2	5.7	6.6

Source: Company data, Centrum Research Estimates

*Note – Financials from FY17 account for Ind-AS & merger

Exhibit 8: Balance Sheet

Y/E Mar(Rs mn)	FY15	FY16	FY17	FY18E	FY19E
Equity Share Capital	346	346	360	360	360
Reserves & surplus	3,102	3,521	6,484	6,818	7,259
Shareholders' fund	3,448	3,867	6,845	7,179	7,620
Total Debt	1,162	835	807	357	157
Def tax liab. (net)	108	112	63	63	63
Minority interest	96	129	0	0	0
Total Liabilities	4,814	4,942	7,714	7,599	7,840
Gross Block	4,064	4,353	7,009	7,259	7,459
Less: Acc. Depreciation	1,584	1,778	2,219	2,670	3,135
Net Block	2,480	2,575	4,789	4,589	4,324
Capital WIP	41	20	16	16	16
Net Fixed Assets	2,521	2,595	4,805	4,605	4,340
Investments	5	85	115	115	115
Inventories	1,002	772	936	918	1,023
Sundry debtors	1,803	1,803	2,283	2,077	2,313
Cash	479	557	560	896	1,182
Loans & Advances	104	136	237	153	170
Other assets	39	33	36	36	36
Total Current Asset	3,427	3,301	4,053	4,081	4,724
Trade payables	1,000	990	1,192	1,093	1,217
Other current Liab.	30	27	61	22	24
Provisions	108	22	6	87	97
Net Current Assets	2,288	2,262	2,794	2,878	3,385
Total Assets	4,814	4,942	7,714	7,599	7,840

Source: Company data, Centrum Research Estimates

Exhibit 9: Cash Flow

Y/E Mar(Rs mn)	FY15	FY16	FY17	FY18E	FY19E
Operating profit bef working capital changes	1,022	820	1,071	1,024	1,210
Changes in working capital	(119)	180	(600)	251	(221)
Cash flow from operations	635	830	275	1,130	797
Adj. OCF (OCF - Interest)	577	783	230	1,108	787
Net Capex	198	167	130	250	200
Adj. FCF	379	615	100	858	587
Cash flow from investments	(165)	(222)	(2)	(220)	(167)
Cash flow from financing	(275)	(549)	(41)	(573)	(344)
Net change in cash	176	70	140	336	285

Source: Company data, Centrum Research Estimates



Appendix A

Disclaimer

Centrum Broking Limited ("Centrum") is a full-service, Stock Broking Company and a member of The Stock Exchange, Mumbai (BSE) and National Stock Exchange of India Ltd. (NSE). Our holding company, Centrum Capital Ltd, is an investment banker and an underwriter of securities. As a group Centrum has Investment Banking, Advisory and other business relationships with a significant percentage of the companies covered by our Research Group. Our research professionals provide important inputs into the Group's Investment Banking and other business selection processes.

Recipients of this report should assume that our Group is seeking or may seek or will seek Investment Banking, advisory, project finance or other businesses and may receive commission, brokerage, fees or other compensation from the company or companies that are the subject of this material/report. Our Company and Group companies and their officers, directors and employees, including the analysts and others involved in the preparation or issuance of this material and their dependants, may on the date of this report or from, time to time have "long" or "short" positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. Centrum or its affiliates do not own 1% or more in the equity of this company Our sales people, dealers, traders and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. We may have earlier issued or may issue in future reports on the companies covered herein with recommendations/ information inconsistent or different those made in this report. In reviewing this document, you should be aware that any or all of the foregoing, among other things, may give rise to or potential conflicts of interest. We and our Group may rely on information barriers, such as "Chinese Walls" to control the flow of information contained in one or more areas within us, or other areas, units, groups or affiliates of Centrum or its affiliates do not make a market in the subject company's securities at the time that the research report was published.

This report is for information purposes only and this document/material should not be construed as an offer to sell or the solicitation of an offer to buy, purchase or subscribe to any securities, and neither this document nor anything contained herein shall form the basis of or be relied upon in connection with any contract or commitment whatsoever. This document does not solicit any action based on the material contained herein. It is for the general information of the clients of Centrum. Though disseminated to clients simultaneously, not all clients may receive this report at the same time. Centrum will not treat recipients as clients by virtue of their receiving this report. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Similarly, this document does not have regard to the specific investment objectives, financial situation/circumstances and the particular needs of any specific person who may receive this document. The securities discussed in this report may not be suitable for all investors. The securities described herein may not be eligible for sale in all jurisdictions or to all categories of investors. The countries. The appropriateness of a particular investment or strategy will depend on an investor's or dealings in securities by nationals of other countries. The appropriateness of a particular investment or strategy will depend on an investor's individual circumstances and objectives. Persons who may receive this document should consider and independently evaluate whether it is suitable for his/her/their own investigation and analysis of the information contained or referred to in this document and of evaluating the merits and risks involved in the securities forming the subject matter of this document.

The projections and forecasts described in this report were based upon a number of estimates and assumptions and are inherently subject to significant uncertainties and contingencies. Projections and forecasts are necessarily speculative in nature, and it can be expected that one or more of the estimates on which the projections and forecasts were based will not materialize or will vary significantly from actual results, and such variances will likely increase over time. All projections and forecasts described in this report have been prepared solely by the authors of this report independently of the Company. These projections and forecasts were not prepared with a view toward compliance with published guidelines or generally accepted accounting principles. No independent accountants have expressed an opinion or any other form of assurance on these projections or forecasts. You should not regard the inclusion of the projections and forecasts described herein as a representation or warranty by or on behalf of the Company, Centrum, the authors of this report or any other person that these projections or forecasts or their underlying assumptions will be achieved. For these reasons, you should only consider the projections and forecasts described in this report after carefully evaluating all of the information in this report, including the assumptions underlying such projections and forecasts.

The price and value of the investments referred to in this document/material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance. Future returns are not guaranteed and a loss of original capital may occur. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice. Centrum does not provide tax advice to its clients, and all investors are strongly advised to consult regarding any potential investment. Centrum and its affiliates accept no liabilities for any loss or damage of any kind arising out of the use of this report. Foreign currencies denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies effectively assume currency risk. Certain transactions including those involving futures, options, and other derivatives as well as non-investment-grade securities give rise to substantial risk and are not suitable for all investors. Please ensure that you have read and understood the current risk disclosure documents before entering into any derivative transactions.

This report/document has been prepared by Centrum, based upon information available to the public and sources, believed to be reliable. No representation or warranty, express or implied is made that it is accurate or complete. Centrum has reviewed the report and, in so far as it includes current or historical information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed. The opinions expressed in this document/material are subject to change without notice and have no obligation to tell you when opinions or information in this report change.

This report or recommendations or information contained herein do/does not constitute or purport to constitute investment advice in publicly accessible media and should not be reproduced, transmitted or published by the recipient. The report is for the use and consumption of the recipient only. This publication may not be distributed to the public used by the public media without the express written consent of Centrum. This report or any portion hereof may not be printed, sold or distributed without the written consent of Centrum.

The distribution of this document in other jurisdictions may be restricted by law, and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Neither Centrum nor its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information.

This document does not constitute an offer or invitation to subscribe for or purchase or deal in any securities and neither this document nor anything contained herein shall form the basis of any contract or commitment whatsoever. This document is strictly confidential and is being furnished to you solely for your information, may not be distributed to the press or other media and may not be reproduced or redistributed to any other person. The distribution of this report in other jurisdictions may be restricted by law and persons into whose possession this report comes should inform themselves about, and observe any such restrictions. By accepting this report, you agree to be bound by the fore going limitations. No representation is made that this report is accurate or complete.

The opinions and projections expressed herein are entirely those of the author and are given as part of the normal research activity of Centrum Broking and are given as of this date and are subject to change without notice. Any opinion estimate or projection herein constitutes a view as of the date of this report and there can be no assurance that future results or events will be consistent with any such opinions, estimate or projection.

This document has not been prepared by or in conjunction with or on behalf of or at the instigation of, or by arrangement with the company or any of its directors or any other person. Information in this document must not be relied upon as having been authorized or approved by the company or its directors or any other person. Any opinions and projections contained herein are entirely those of the authors. None of the company or its directors or any other person accepts any liability whatsoever for any loss arising from any use of this document or its contents or otherwise arising in connection therewith.

Centrum and its affiliates have not managed or co-managed a public offering for the subject company in the preceding twelve months. Centrum and affiliates have not received compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for service in respect of public offerings, corporate finance, debt restructuring, investment banking or other advisory services in a merger/acquisition or some other sort of specific transaction.

As per the declarations given by them, Mr. Abhisar Jain research, analyst and and/or any of his family members do not serve as an officer, director or any way connected to the company/companies mentioned in this report. Further, as declared by him, he has not received any compensation from the above companies in the preceding twelve months. He does not hold any shares by him or through his relatives or in case if holds the shares then will not to do any transactions in the said scrip for 30 days from the date of release such report. Our entire research professionals are our employees and are paid a salary. They do not have any other material conflict of interest of the research analyst or member of which the research analyst knows of has reason to know at the time of publication of the research report or at the time of the public appearance.

While we would endeavour to update the information herein on a reasonable basis, Centrum, its associated companies, their directors and employees are under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent Centrum from doing so.

Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or Centrum policies, in circumstances where Centrum is acting in an advisory capacity to this company, or any certain other circumstances.

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject Centrum Broking Limited or its group companies to any registration or licensing requirement within such jurisdiction. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom.

The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market.

IFGL Refractories price chart



Source: Bloomberg, Centrum Research



	Disclosure of Interest Statement				
1	Business activities of Centrum Broking Limited (CBL)	Centrum Broking Limited (hereinafter referred to as "CBL") is a registered member of NSE (Cash, F&O and Currency Derivatives Segments), MCX-SX (Currency Derivatives Segment) and BSE (Cash segment), Depository Participant of CDSL and a SEBI registered Portfolio Manager.			
2	Details of Disciplinary History of CBL	CBL has not been debarred/ suspended by SEBI or any other regulatory authority from accessing /dealing in securities market.			
3	Registration status of CBL:	CBL is registered with SEBI as a Research Analyst (SEBI Registration No. INH000001469)			

		IFGL Refractories	Vesuvius India	Orient Refractories
4	Whether Research analyst's or relatives' have any financial interest in the subject company and nature of such financial interest	No	No	No
5	Whether Research analyst or relatives have actual / beneficial ownership of 1% or more in securities of the subject company at the end of the month immediately preceding the date of publication of the document.	No	No	No
6	Whether the research analyst or his relatives has any other material conflict of interest	No	No	No
7	Whether research analyst has received any compensation from the subject company in the past 12 months and nature of products / services for which such compensation is received	No	No	No
8	Whether the Research Analyst has received any compensation or any other benefits from the subject company or third party in connection with the research report	No	No	No
9	Whether Research Analysts has served as an officer, director or employee of the subject company	No	No	No
10	Whether the Research Analyst has been engaged in market making activity of the subject company.	No	No	No

Rating Criteria

Rating	Market cap < Rs20bn	Market cap > Rs20bn but < 100bn	Market cap > Rs100bn		
Buy	Upside > 20%	Upside > 15%	Upside > 10%		
Hold	Upside between -20% to +20%	Upside between -15% to +15%	Upside between -10% to +10%		
Sell	Downside > 20%	Downside > 15%	Downside > 10%		

Member (NSE and BSE)

Regn No.:

CAPITAL MARKET SEBI REGN. NO.: BSE: INB011454239 CAPITAL MARKET SEBI REGN. NO.: NSE: INB231454233 DERIVATIVES SEBI REGN. NO.: NSE: INF231454233 (TRADING & CLEARING MEMBER) CURRENCY DERIVATIVES: MCX-SX INE261454230 CURRENCY DERIVATIVES:NSE (TM & SCM) – NSE 231454233

Depository Participant (DP)

CDSL DP ID: 120 – 12200 SEBI REGD NO. : CDSL : IN-DP-CDSL-661-2012

PORTFOLIO MANAGER

SEBI REGN NO.: INP000004383

Website: www.centrum.co.in Investor Grievance Email ID: investor.grievances@centrum.co.in

> Compliance Officer Details: Kavita Ravichandran

(022) 4215 9842; Email ID: **C**ompliance@centrum.co.in

Centrum Broking Ltd. (CIN :U67120MH1994PLC078125)

Registered Office Address

Bombay Mutual Building , 2nd Floor, Dr. D. N. Road, Fort, Mumbai - 400 001 Corporate Office & Correspondence Address Centrum House 6th Floor, CST Road, Near Vidya Nagari Marg, Kalina, Santacruz (E), Mumbai 400 098. Tel: (022) 4215 9000